19 results about "Notoginsenoside R1" patented technology

The application discloses an application of a kit for detecting a SNP molecular marker related to the content of ginsenoside R1 in Panax notoginseng to breeding of the content of ginsenoside R1 in Panax notoginseng, wherein the SNP molecular marker is SNP5-188995192, is located at the base of 188995192 of Chr5 chromosome, and the mutation type is G / C. The KASP primer combination developed in the application can accurately distinguish Panax notoginseng with high and low contents of ginsenoside R1, and can be applied to molecular assisted marker breeding of Panax notoginseng, shortens the breeding cycle of new varieties, and has low detection cost, is not limited by environment, has high accuracy of detection results, and is easy to repeat. The application has important theoretical and practical guiding significance for accelerating the genetic improvement process of Panax notoginseng with high content of ginsenoside R1 and improving the selection efficiency of breeding.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

The application discloses Jianyang capsule fingerprint spectrum and a construction method and application thereof, and relates to the technical field of quality detection. The construction method of the Jianyang capsule fingerprint spectrum comprises the following steps: preparing a control solution by using ginsenoside Rg1, ginsenoside Rb1, notoginsenoside R1, ganoderic acid A, primulaverin and 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside; preparing a test solution by using powders of Jianyang capsules of different batches; and performing high performance liquid chromatography analysis on the control solution and the test solution respectively to generate the Jianyang capsule fingerprint spectrum. The main peak and each chromatographic peak of the Jianyang capsule fingerprint spectrum obtained by the application are well separated, the Jianyang capsule fingerprint spectrum is applied to quality control detection of Jianyang capsules, the quality of the products can be comprehensively monitored, the consistency, controllability and stability of the product quality are ensured, and therefore, the quality of the Jianyang capsule products can be more comprehensively monitored.

The application discloses application of a glycosyltransferase Bs-YjiC in Bacillus subtilis 168 and comprises the following steps: catalyzing reaction of ginsenoside Rg2, the glycosyltransferase Bs-YjiC and uridine diphosphate glucose, so as to glycosylate C 20 hydroxyl group of the ginsenoside Rg2 to generate ginsenoside Re; or catalyzing reaction of notoginsenoside R2, the glycosyltransferase Bs-YjiC and uridine diphosphate glucose, so as to glycosylate C 20 hydroxyl group of the notoginsenoside R2 to generate notoginsenoside R1; the application utilizes the glycosyltransferase Bs-YjiC of microbial origin to catalyze C 20 hydroxyl group glycosylation of the ginsenoside Rg2 or the notoginsenoside R2, and since the ginsenoside Re and the notoginsenoside R1 have important pharmacological effects, the glycosyltransferase Bs-YjiC of microbial origin can be utilized to catalyze synthesis of the ginsenoside Re and the notoginsenoside R1 beneficial to human health.

The invention belongs to the technical field of traditional Chinese medicines, and provides a pharmaceutical composition containing an effective component of American ginseng, a pharmaceutical preparation and application of the pharmaceutical composition and the pharmaceutical preparation in treating chronic obstructive pulmonary diseases. The pharmaceutical composition is prepared from the following components in parts by weight: 1 to 2 parts of ginsenoside Rg1, 1 to 2 parts of ginsenoside Rc, 0.5 to 1 part of oleanolic acid, 0.1 to 0.5 part of notoginsenoside R1 and 0.05 to 0.1 part of notoginsenoside Fe. Specific American ginseng saponin components are compounded, and the dosage of each component is optimized, so that the composition has remarkable effects of protecting the lung function of a COPD mouse caused by cigarette smoke exposure, inhibiting expression of inflammatory factors and relieving in-vivo oxidative stress injury, the repairing effect is remarkable, and in order to improve the effect of American ginseng in treatment of COPD, the composition has a good application prospect. And an important basis is provided for fully exerting the effects of all active components in the American ginseng.

The invention relates to the technical field of health-care food, in particular to a pseudo-ginseng oral liquid and a preparation method and application thereof, and the pseudo-ginseng oral liquid comprises the following components in percentage by weight: 20-40% of pseudo-ginseng root extract, 3-8% of pseudo-ginseng stem and leaf extract, 0.5-2% of pseudo-ginseng flower extract and the balance of purified water. The total saponin is not less than 1200 mg / 100 mL in terms of ginsenoside Re, the ginsenoside Rb1 is not less than 30 wt%, the ginsenoside Rg1 is not less than 25 wt%, and the notoginsenoside R1 is not less than 5 wt%. The pH value of the product is 4.5-7.5, the product meets strict physicochemical and microbial standards, the product is packaged by a sodium-calcium glass bottle, and the shelf life is 24 months. The preparation method comprises the following steps: exclusively extracting, purifying, preparing, sterilizing and the like, and realizing quality controllability through an HPLC (High Performance Liquid Chromatography) characteristic chromatogram. The preparation is reasonable in dosage form, the problems of moisture absorption, low bioavailability and the like of a solid preparation are solved, and the active components are easy to absorb and convenient to take. Through research, the health-care tea has the health-care functions of improving hypoxia tolerance and relieving physical fatigue, and is suitable for people with related requirements.

The application provides a blood-activating and stasis-removing medicinal composition containing fermented douchi and a preparation method thereof, belongs to the technical field of biological medicine, and the medicinal composition comprises fermented douchi, drynaria extract, extract of pereskia aculeata, tanshinone II A, notoginsenoside R1, ligustrazine, rhodioside, total flavones of hawthorn leaves and total flavones of mulberry leaves. The fermented douchi is prepared from soybeans and black beans through fermentation by bacillus subtilis and bacillus coagulans. The drynaria extract is prepared from drynaria powder through common enzymolysis by cellulase, chitinase and beta-glucanase, extraction by a two-phase solvent, and purification by a dextran gel column. The extract of pereskia aculeata is prepared from pereskia aculeata powder through common enzymolysis by pectinase, cellulase and xylanase, common enzymolysis by bromelain and subtilisin, and purification by a macroporous adsorption resin column. The medicinal components are prepared in a specific proportion to relieve blood stasis from two dimensions of "improving blood flow dynamics + preventing thrombus formation".

The invention discloses a method for simultaneously determining seven mass markers (Q-Marker) in serum of traditional Chinese medicine particles for treating cervical pain, which is characterized in that the seven mass markers are magnoflorine, puerarin, tetrahydropalmatine, paeoniflorin, notoginsenoside R1, ligustilide and decuricin; the method comprises the following steps: adding a serum sample into acetonitrile and acetone, carrying out vortex and centrifugation, taking a supernatant, loading the supernatant into a Hybrid SPEcolumn, washing with water to remove salt and polar interferents, eluting a target analyte with acetonitrile, filtering the eluent through a microfiltration membrane, carrying out sample introduction determination, and carrying out quantitative analysis by adopting a high performance liquid chromatography-mass spectrometry method and an electrospray ion source. And quantitative analysis is carried out in a positive / negative ion multi-reaction monitoring detection mode. The method is efficient, sensitive and high in selectivity, and solves the problems of serious matrix interference, indefinite target components, difficulty in simultaneous analysis of multiple components and the like in the prior art.

The invention relates to a gingerous notoginsenoside R1-metal ion self-assembled hydrogel and a preparation method thereof. The self-assembled hydrogel comprises gingerous notoginsenoside R1, metal ions and a solvent, wherein the concentration of the notoginsenoside R1 and the concentration of the metal ions are both 1-100 mmol / L; the metal ions comprise at least one of divalent metal ions and trivalent metal ions. According to the invention, divalent metal ions or trivalent metal ions are used for generating coordination, so that the gingerous notoginsenoside R1 forms the self-assembled hydrogel, and a thickening agent does not need to be added; in the obtained hydrogel, metal ions are distributed in the gingerous notoginsenoside R1, and the gingerous notoginsenoside R1 can reach a relatively high concentration; meanwhile, the self-assembled hydrogel has excellent stability, and can still maintain the gel form after being inverted for 48 hours; the preparation process is simple, the preparation of the self-assembled hydrogel can be completed without heating, and the preparation method is suitable for industrial production.

This invention belongs to the field of biomedical technology, specifically relating to a composition for treating ischemic heart disease and its application. This invention combines two or more of ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, and notoginsenoside R1, which can significantly downregulate the levels of myocardial enzymes, aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) in myocardial coronary effusion, with an inhibitory effect significantly higher than that of a single saponin component and the positive control drug verapamil. Simultaneously, the composition exhibits better recovery capabilities for coronary flow (CF), left ventricular developmental pressure (LVDP), maximum rate of decrease in left ventricular pressure (-dp / dtmax), and heart rate (HR) in myocardial coronary effusion. Therefore, the composition can alleviate and treat myocardial ischemia-reperfusion injury through multiple targets and mechanisms, fundamentally inhibiting the development of ischemic heart disease.

The invention discloses a preparation method and application of an anti-inflammatory and vascularization-promoting sequential drug release composite fiber dressing, the dressing is loaded with functionalized core-shell structure nanoparticles NGR1-cMSN-coated CMOFs, and the nanoparticles are loaded with a vascularization-promoting drug notoginsenoside R1 by taking carboxylated mesoporous silica (cMSN) in an inner layer as a core; the metal organic framework ZIF-8 on the outer layer is used as a shell, and an anti-inflammatory drug curcumin is loaded. Through the exquisite core-shell structure design, sequential release of drugs in the wound repair process is achieved: the ZIF-8 layer firstly responds to the subacid environment of the wound to be rapidly degraded, and curcumin is released for early-stage anti-inflammation; then, the notoginsenoside R1 is slowly released by the mesoporous silicon dioxide core, and later angiogenesis is promoted. The synergistic effect mechanism of first anti-inflammation and then blood vessel promotion can effectively overcome the healing disorder of the diabetic wound and significantly accelerate the wound repair process. The dressing prepared by the invention has good biocompatibility and repairing function, and has wide application prospect in the field of chronic wound treatment.

The invention relates to the technical field of biomedical materials, in particular to a chitosan-hyaluronic acid hydrogel composition based on astragaloside and salvianolic acid B as well as a preparation method and application of the chitosan-hyaluronic acid hydrogel composition. According to the hydrogel, a three-dimensional network formed by synergistic crosslinking of chitosan and hyaluronic acid is constructed, various natural active ingredients including astragaloside, salvianolic acid B, ferulic acid and notoginsenoside R1 are loaded, and the composite hydrogel with good biocompatibility, controllable degradability and anti-inflammatory and anti-adhesion functions is formed. C-S covalent crosslinking is realized by adopting a maleimide-cysteine system, so that the structural stability and the component release efficiency are improved. Animal experiment results show that the hydrogel can significantly reduce postoperative adhesion score and inflammatory factor level, and has wide postoperative anti-adhesion application potential.

The invention discloses a traditional Chinese medicine compound cell culture fluid and application thereof. The traditional Chinese medicine compound cell culture fluid comprises a basic culture medium, and 1 L of the basic culture medium contains 2-10 mg of notoginsenoside R1, 1-5 mg of notoginsenoside Rb1, 1-5 mg of notoginsenoside Rg1, 0.1-1 mg of notoginsenoside Rg3, 0.5-2 mg of notoginsenoside Re, 1-6 [mu] g of shikonin, 5-15 [mu] g of cordycepin and 1-20 mg of basil polysaccharide. In the traditional Chinese medicine compound cell culture fluid, notoginsenoside Rg3 can be combined with shikonin, so that the cytotoxicity can be enhanced, cord blood NK cells are promoted to be differentiated to mature functional phenotypes with high cytotoxic activity, and the killing efficiency of the NK cells on various tumor target cells is remarkably improved; the notoginsenoside Rb1 is combined with the basil polysaccharide, so that the NK cells can be driven to expand and grow, the activity of the NK cells can be maintained, and the cell purity can be improved, so that the persistence of the cell activity can be enhanced, and the tumor killing rate of the NK cells can be improved.

The invention relates to the technical field of application processes of traditional Chinese medicine compositions, and particularly discloses an application method of a traditional Chinese medicine composition for treating common diseases of diabetes and coronary heart disease, and the application method comprises the following steps: pre-treating astragalus membranaceus, dried dendrobe, radix puerariae, pseudo-ginseng, salvia miltiorrhiza, coptis chinensis tablets and lophatherum gracile for later use; crushing pseudo-ginseng to prepare pseudo-ginseng micro-capsules; carrying out segmented targeted extraction on water-soluble components and fat-soluble components in the traditional Chinese medicine components; integrating the two extracting solutions, adding the pseudo-ginseng micro-capsules, grinding, and sequentially performing concentration, sterilization and filling treatment. According to the invention, the dissolution rate of effective components in the traditional Chinese medicine composition is improved and the use effect is enhanced through a segmented targeted extraction process of the water-soluble component and the fat-soluble component; meanwhile, the retention rate of notoginsenoside R1 is increased through a pseudo-ginseng micro-capsule preparation process; in addition, bottled liquid is prepared, a traditional decocting application method of traditional Chinese medicine is abandoned, the purity of the liquid medicine is greatly improved, and the preservation time is greatly prolonged.

The invention provides a medicine composition containing fermented soya beans and capable of promoting blood circulation to remove blood stasis and a preparation method of the medicine composition, and belongs to the technical field of biological medicines.The medicine composition comprises the fermented soya beans, thelephora ganbajun extract, holboellia latifolia rind extract, tanshinone IIA, notoginsenoside R1, ligustrazine, salidroside, hawthorn leaf total flavonoids and mulberry leaf total flavonoids. The fermented soybeans are prepared by fermenting soybeans and black beans through bacillus subtilis and bacillus coagulans. The thelephora ganbajun Zang extract is prepared by carrying out common enzymolysis on thelephora ganbajun Zang powder through cellulase, chitinase and beta-glucanase, extracting through a two-phase solvent and purifying through a sephadex column. The stauntonia latifolia rind extract is prepared by performing common enzymolysis on stauntonia latifolia rind powder through pectinase, cellulase and xylanase, performing common enzymolysis on stauntonia latifolia rind powder through bromelain and subtilisin and purifying the stauntonia latifolia rind powder through a macroporous adsorption resin column. The medicine components are prepared according to a specific proportion, and blood vessel stasis is relieved from the two dimensions of improving hemodynamic force and preventing thrombosis.

The application discloses a kind of detection and ginsenoside R1 content related SNP molecular marker kit in ginseng in ginsenoside R1 content character breeding in ginseng, its characterized in that: the SNP molecular marker is SNP2-188997159, located in the 188997159 base of Chr5 chromosome, and its mutation type is G / A.The KASP primer combination developed in the application can accurately distinguish ginsenoside R1 content high and low ginseng, and can be applied to ginseng molecular assisted marker breeding, shorten new variety cultivation cycle, and detection cost is lower, not limited by environment, detection result accuracy is high, easy to repeat.For speeding up the genetic improvement process of high ginsenoside R1 content ginseng breeding, it has important theoretical and practical guiding significance to improve breeding selection efficiency.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine white panax notoginseng steaming processing quality control method, which comprises the following steps: mixing ginsenoside Ro, pseudoginsenoside RT1, panax japonicus saponin IV, panax japonicus saponin IVa, gingerous notoginsenoside R1, pseudo-ginsenoside RP1, calendula officinalis glycoside E, oleanolic acid beta-D-glucopyranose ester, ginsenoside RK1 and ethanol, stirring, filtering, and drying to obtain a finished product. Obtaining a reference substance solution; grinding and sieving the steamed white pseudo-ginseng powder, adding the powder into ethanol or methanol, uniformly stirring, performing ultrasonic extraction, fixing the volume, centrifuging and collecting supernate to obtain a test solution; the reference solution and the test solution are injected into a high performance liquid chromatograph for content detection, the retention time RSD of the nine components is smaller than 0.85%, the peak area RSD of the nine components is smaller than 2.44%, and therefore the detection and analysis method has good precision.

This invention discloses a kit for detecting SNP molecular markers related to the content of notoginsenoside R1 in Panax notoginseng, and its application in breeding for the trait of notoginsenoside R1 content in Panax notoginseng. The SNP molecular marker is SNP9-188989821, located at base position 188989821 on chromosome 5, with a mutation type of C / G. The KASP primer combination developed in this invention can accurately distinguish between Panax notoginseng with high and low notoginsenoside R1 content, and can be applied to molecular marker-assisted breeding of Panax notoginseng, shortening the breeding cycle of new varieties. Furthermore, the detection cost is low, it is not limited by the environment, and the detection results are highly accurate and easily reproducible. This has important theoretical and practical guiding significance for accelerating the genetic improvement process of breeding Panax notoginseng with high notoginsenoside R1 content and improving breeding selection efficiency.

This invention relates to glycosyltransferase and an application thereof. Specifically, provided is using glycosyltransferase GT29-32, GT29-33, GT29-34, GT29-4, GT29-5, GT29-7, GT29-9, GT29-11, GT29-13, GT29-17, GT29-18, GT29-19, GT29-20, GT29-21, GT29-22, GT29-23, GT29-24, GT29-25, GT29-36, GT29-37, GT29-42, GT29-43, GT29-45, GT29-46, PNUGT29-1, PNUGT29-2, PNUGT29-3, PNUGT29-4, PNUGT29-5, PNUGT29-6, PNUGT29-7, PNUGT29-8, PNUGT29-9, PNUGT29-14, and PNUGT29-15, and derived polypeptides thereof to catalyze the first glycosyl at position C-20, the first glycosyl at position C-6, and the first glycosyl at position C-3 of a tetracyclic triterpene compound substrate to elongate a carbohydrate chain, thereby obtaining a catalytic reaction of ginsenoside products such as ginsenoside Rg3, ginsenoside Rd, ginseno-side Rb 1, ginsenoside Rb3, saponin DMGG, saponin DMGX, gypenoside LXXV, gypenoside XVII, gypenoside XIII, gypenoside IX, notoginsenoside U, and notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-0-13-(D-xylopyranosyl)-13-(D-glucopyra-nosyl)-PPD, 3-0-13-(D-xylopyranosyl)-13-(D-glucopyranosyl)-CK, 20-O-Glucosylginsenoside Rf, and Ginsenoside F3. The glycosyltransferase can further be applied to construction of artificially synthesized ginsenoside, novel ginsenoside, and derivatives thereof.